Q1 EPS Estimate for Rapport Therapeutics Lifted by Analyst

Rapport Therapeutics, Inc. (NASDAQ:RAPP) – Research analysts at HC Wainwright raised their Q1 2026 earnings estimates for Rapport Therapeutics in a research note issued to investors on Wednesday, March 11th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per share of ($0.65) for the quarter, up from their prior forecast of ($0.76). HC Wainwright has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for Rapport Therapeutics’ current full-year earnings is ($3.65) per share. HC Wainwright also issued estimates for Rapport Therapeutics’ Q2 2026 earnings at ($0.26) EPS, Q3 2026 earnings at ($0.70) EPS, Q4 2026 earnings at ($0.78) EPS, FY2026 earnings at ($2.40) EPS, FY2027 earnings at ($3.56) EPS, FY2028 earnings at ($4.65) EPS and FY2029 earnings at ($4.78) EPS.

RAPP has been the topic of several other reports. TD Cowen reiterated a “buy” rating on shares of Rapport Therapeutics in a research note on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Rapport Therapeutics in a research report on Thursday, January 22nd. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Rapport Therapeutics in a report on Friday, December 19th. Wall Street Zen upgraded Rapport Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Finally, Citigroup restated a “market outperform” rating on shares of Rapport Therapeutics in a research report on Tuesday. Eight analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $51.40.

Rapport Therapeutics Stock Down 6.1%

Shares of RAPP opened at $28.67 on Friday. Rapport Therapeutics has a twelve month low of $7.73 and a twelve month high of $42.27. The stock has a market cap of $1.37 billion, a PE ratio of -10.02 and a beta of 1.51. The business’s 50-day moving average price is $28.11 and its 200-day moving average price is $26.90.

Rapport Therapeutics (NASDAQ:RAPP) last posted its quarterly earnings results on Tuesday, March 10th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.07).

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Affinity Asset Advisors LLC purchased a new stake in Rapport Therapeutics during the second quarter valued at about $2,270,000. Capital International Investors boosted its holdings in shares of Rapport Therapeutics by 30.7% in the 3rd quarter. Capital International Investors now owns 3,402,529 shares of the company’s stock worth $101,055,000 after purchasing an additional 800,000 shares in the last quarter. Intech Investment Management LLC bought a new position in shares of Rapport Therapeutics during the 2nd quarter valued at about $130,000. China Universal Asset Management Co. Ltd. increased its position in shares of Rapport Therapeutics by 45.5% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,766 shares of the company’s stock valued at $327,000 after purchasing an additional 3,368 shares during the last quarter. Finally, Tudor Investment Corp ET AL purchased a new position in shares of Rapport Therapeutics during the 3rd quarter valued at about $331,000.

Insider Activity at Rapport Therapeutics

In other Rapport Therapeutics news, insider David Bredt sold 8,500 shares of Rapport Therapeutics stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $29.02, for a total transaction of $246,670.00. Following the completion of the sale, the insider directly owned 387,075 shares in the company, valued at $11,232,916.50. The trade was a 2.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Krishnaswamy Yeleswaram sold 2,840 shares of the stock in a transaction on Wednesday, December 31st. The stock was sold at an average price of $30.05, for a total transaction of $85,342.00. Following the completion of the transaction, the insider directly owned 296,991 shares in the company, valued at $8,924,579.55. The trade was a 0.95% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 69,669 shares of company stock valued at $1,999,877. Company insiders own 13.57% of the company’s stock.

Rapport Therapeutics News Summary

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a Buy and raised multiple near-term EPS forecasts (Q1–Q4 2026 and FY2026–2028), marking sizeable improvements to FY2026 (from -$3.16 to -$2.40) and trimming some later-year losses — this supports a constructive view on RAP-219 development progress and a $40 price target. Advancing RAP-219: Phase 3 Progress, 2026 Catalysts, and Strategic China Partnership Support a Buy Rating
• Positive Sentiment: Wells Fargo raised its price target to $46 and assigned an “overweight” rating — a higher target from a major bank can boost investor confidence and act as support for the stock. Wells Fargo raises price target
• Neutral Sentiment: HC Wainwright provided longer-term FY2029/FY2030 estimates (mixed changes across distant years) — useful for modeling but less likely to drive near-term moves compared with the recent earnings print and near‑term guidance. Analyst long-term estimates
• Neutral Sentiment: A regulatory filing/annual report notice (non-U.S.) appeared in the feed but is not clearly related to RAPP’s U.S. operations or clinical program timelines — likely immaterial to near-term U.S. trading. Mise à disposition des éléments préparatoires
• Negative Sentiment: RAPP reported quarterly results that missed estimates (reported EPS of -$0.72 vs. consensus -$0.65), and the shares gapped down after that print — the earnings miss is the primary near-term catalyst putting downward pressure on the stock. Rapport Therapeutics Shares Gap Down After Earnings Miss

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.